[Recent advances in the application of TAT, TM, t-PAIC and PIC in thromboembolism].

Thromboembolism is a crucial part of the global disease burden. It has high incidence, high mortality and disability rates, and the mechanism of occurrence and development is extremely complex. It is difficult to detect the disease in the early stage so that we have trouble with clinical prevention and treatment in general. At present, four items of blood coagulation and D-dimer have been widely used in the evaluation and auxiliary diagnosis of thromboembolism, the monitoring of effect for antithrombotic drugs and other fields. The thrombus biomarkers including thrombin-antithrombin complex (TAT), thrombomodulin (TM), tissue plasminogen activator-inhibitor complex (t-PAIC) and α2-plasmin inhibitor-plasmin complex (PIC) fill the gap of laboratory diagnosis before clinical symptoms appear in some degree. This article aims to explain the current application status of TAT, TM, t-PAIC and PIC in thromboembolism and explore their potential application value, so as to provide a reference for selecting appropriate early monitoring indicators for high-risk population of thromboembolism.血栓栓塞是全球疾病负担的重要组成部分，其发病率高，致死、致残率高，且发生、发展机制极其复杂，疾病早期难以察觉，因此临床防治具有一定难度。当前，常规凝血四项、D-二聚体等实验室检查已广泛应用于血栓栓塞的评估与辅助诊断、抗血栓药物的效果监测等领域。而凝血酶-抗凝血酶复合物（TAT）、血栓调节蛋白（TM）、组织纤溶酶原激活物-抑制剂1复合物（t-PAIC）、纤溶酶-α2纤溶酶抑制物复合物（PIC）等血栓生物标志物在一定程度上填补了临床症状出现前实验室诊断的空白。本文旨在阐释TAT、TM、t-PAIC、PIC在血栓栓塞中的应用现状并发掘其潜在的应用价值，为血栓栓塞高危人群选择合适的早期监测指标提供参考。.